Back to All

Labs interested in NTRK IHC proficiency testing will be at the front row of Quality on DXRX

14 February, 2021

Diaceutics recently launched DXRX, the world’s first diagnostic network for precision medicine. This digital platform facilitates dynamic, real-time collaborations that enable the accurate delivery of personalized therapeutics. This marketplace presents an ideal opportunity for stakeholders in precision medicine, who wish to accelerate the implementation of quality testing required, to deliver on companion diagnostic dependent innovative care, that benefits an increasing number of patients, in a speed never before possible for precision medicine stakeholders.    

A perfect example of a collaboration on DXRX, is the partnership between Diaceutics and the Canadian Pathology Quality Assurance (CPQA)1. Through this partnership, CPQA is looking to support their global implementation of a pan-TRK program, which will produce best-in-class Neurotrophic Tropomyosin Receptor Kinase IHC proficiency testing.

DXRX provides CPQA with the opportunity of engagement with an extensive network of labs at the global level, while CPQA provides the labs with validation assistance and proficiency testing in NTRK IHC. This dynamic, interactive process on the platform, significantly reduces the time previously required for labs to enter such a program.

In this way, labs have now the opportunity to be at the front row of quality on DXRX while being able to access sponsored programs and collaborations.

The CPQA pan-TRK EQA program is free of charge and it is on the platform’s marketplace live until March 26, 2021. Registration may close once 20 labs have been enrolled.

Register here on DXRX to learn more about collaboration opportunities.


1. Canadian Pathology Quality Assurance leverages Diaceutics’ DXRX platform to advance NTRK IHC proficiency testing - Diaceutics

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics. 

Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.

Public Relations & Investor Relations advisers

Alma PR
71-73 Carter Lane

Tel: +44 (0)20 3405 0205 or [email protected]

Caroline Forde
Robyn Fisher
Kieran Breheny